NlpI facilitates deposition of C4bp on Escherichia coli by blocking classical complement-mediated killing, which results in high-level bacteremia

Infection and Immunity

Volumn 80, Issue 10, 2012, Pages 3669-3678

  Tseng, Yu Ting ^a   Wang, Shainn Wei ^a   Kim, Kwang Sik ^b   Ying Hsiang Wang, ^c,d   Yufeng Yao, ^e   Chien Cheng Chen, ^f   Chi Wu Chiang, ^a   Pao Chuan Hsieh, ^g   Teng, Ching Hao ^a,h  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f NATIONAL KAOHSIUNG NORMAL UNIVERSITY   (Taiwan)

^g NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL PROTEIN; C4BP PROTEIN; NLPI PROTEIN; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; BLOOD BRAIN BARRIER; CELL SURFACE; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; ENDOTHELIUM CELL; ESCHERICHIA COLI; HUMAN; NEWBORN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT;

ANIMALS; ANIMALS, NEWBORN; BACTEREMIA; COMPLEMENT C3B; COMPLEMENT PATHWAY, CLASSICAL; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; HISTOCOMPATIBILITY ANTIGENS; HUMANS; LIPOPROTEINS; MICE; MUTATION; NEUTROPHILS; RANDOM ALLOCATION; SERUM; TIME FACTORS;

EID: 84867609282     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00320-12     Document Type: Article

References (44)

1. Barnich N, Bringer MA, Claret L, Darfeuille-Michaud A. 2004. Involvement of lipoprotein NlpI in the virulence of adherent invasive Escherichia coli strain LF82 isolated from a patient with Crohn's disease. Infect. Immun. 72:2484-2493.
2. Berggard K, Johnsson E, Mooi FR, Lindahl G. 1997. Bordetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutinin. Infect. Immun. 65:3638-3643.
3. Das A, et al. 2001. Differential role of cytosolic phospholipase A2 in the invasion of brain microvascular endothelial cells by Escherichia coli and Listeria monocytogenes. J. Infect. Dis. 184:732-737.
4. Das AK, Cohen PW, Barford D. 1998. The structure of the tetratricopeptide repeats of protein phosphatase 5: implications for TPR-mediated protein-protein interactions. EMBO J. 17:1192-1199.
5. Fujita T, Gigli I, Nussenzweig V. 1978. Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J. Exp. Med. 148:1044-1051.
6. Fujita T, Nussenzweig V. 1979. The role of C4-binding protein and beta 1H in proteolysis of C4b and C3b. J. Exp. Med. 150:267-276.
7. Gigli I, Fujita T, Nussenzweig V. 1979. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc. Natl. Acad. Sci. U. S. A. 76:6596-6600.
8. Glode MP, et al. 1977. Neonatal meningitis due of Escherichia coli K1. J. Infect. Dis. 136(Suppl):S93-S97.
9. Hallstrom T, Jarva H, Riesbeck K, Blom AM. 2007. Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance. J. Immunol. 178:6359-6366.
10. Herpers BL, et al. 2009. Hemolytic assay for the measurement of functional human mannose-binding lectin: a modification to avoid interference from classical pathway activation. J. Immunol. Methods 343:61-63.
11. Huang SH, et al. 1995. Escherichia coli invasion of brain microvascular endothelial cells in vitro and in vivo: molecular cloning and characterization of invasion gene ibe10. Infect. Immun. 63:4470-4475.
12. Jarva H, Ram S, Vogel U, Blom AM, Meri S. 2005. Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J. Immunol. 174:6299-6307.
13. Joens LA, Nuessen ME. 1986. Bactericidal effect of normal swine sera on Treponema hyodysenteriae. Infect. Immun. 51:282-285.
14. Kim BY, Kang J, Kim KS. 2005. Invasion processes of pathogenic Escherichia coli. Int. J. Med. Microbiol. 295:463-470.
15. Kim KS. 2003. Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury. Nat. Rev. Neurosci. 4:376-385.
16. Kim KS, et al. 1988. Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo. J. Infect. Dis. 157:47-53.
17. Lamb JR, Tugendreich S, Hieter P. 1995. Tetratrico peptide repeat interactions: to TPR or not to TPR? Trends Biochem. Sci. 20:257-259.
18. Lerner CG, Inouye M. 1990. Low copy number plasmids for regulated low-level expression of cloned genes in Escherichia coli with blue/white insert screening capability. Nucleic Acids Res. 18:4631.
19. Li K, Sacks SH, Sheerin NS. 2008. The classical complement pathway plays a critical role in the opsonisation of uropathogenic Escherichia coli. Mol. Immunol. 45:954-962.
20. Maruvada R, Kim KS. 2011. Extracellular loops of the Escherichia coli outer membrane protein A contribute to the pathogenesis of meningitis. J. Infect. Dis. 203:131-140.
21. McBroom AJ, Johnson AP, Vemulapalli S, Kuehn MJ. 2006. Outer membrane vesicle production by Escherichia coli is independent of membrane instability. J. Bacteriol. 188:5385-5392.
22. Nordstrom T, Blom AM, Forsgren A, Riesbeck K. 2004. The emerging pathogen Moraxella catarrhalis interacts with complement inhibitor C4b binding protein through ubiquitous surface proteins A1 and A2. J. Immunol. 173:4598-4606.
23. Ogundele MO. 1999. Complement-mediated bactericidal activity of human milk to a serum-susceptible strain of E. coli 0111. J. Appl. Microbiol. 87:689-696.
24. Ohara M, Wu HC, Sankaran K, Rick PD. 1999. Identification and characterization of a new lipoprotein, NlpI, in Escherichia coli K-12. J. Bacteriol. 181:4318-4325.
25. Petersen SV, et al. 2000. Control of the classical and the MBL pathway of complement activation. Mol. Immunol. 37:803-811.
26. Petersen SV, Thiel S, Jensenius JC. 2001. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol. Immunol. 38:133-149.
27. Pluschke G, Mayden J, Achtman M, Levine RP. 1983. Role of the capsule and theOantigen in resistance of O18:K1 Escherichia coli to complementmediated killing. Infect. Immun. 42:907-913.
28. Prasadarao NV, Blom AM, Villoutreix BO, Linsangan LC. 2002. A novel interaction of outer membrane protein A with C4b binding protein mediates serum resistance of Escherichia coli K1. J. Immunol. 169:6352-6360.
29. Robbins JB, et al. 1974. Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N. Engl. J. Med. 290:1216-1220.
30. Scheufler C, et al. 2000. Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. Cell 101:199-210.
31. Silver RP, Aaronson W, Sutton A, Schneerson R. 1980. Comparative analysis of plasmids and some metabolic characteristics of Escherichia coli K1 from diseased and health
32. Tadokoro A, et al. 2004. Interaction of the Escherichia coli lipoprotein NlpI with periplasmic Prc (Tsp) protease. J. Biochem. 135:185-191.
33. Teng CH, et al. 2005. Escherichia coli K1 RS218 interacts with human brain microvascular endothelial cells via type 1 fimbria bacteria in the fimbriated state. Infect. Immun. 73:2923-2931.
34. Teng CH, Palaniappan RU, Chang YF. 2003. Cloning and characterization of an Ehrlichia canis gene encoding a protein localized to the morula membrane. Infect. Immun. 71:2218-2225.
35. Teng CH, et al. 2010. NlpI contributes to Escherichia coli K1 strain RS218 interaction with human brain microvascular endothelial cells. Infect. Immun. 78:3090-3096.
36. Terai I, Kobayashi K. 1993. Perinatal changes in serum mannose-binding protein (MBP) levels. Immunol. Lett. 38:185-187.
37. Terai I, Kobayashi K, Fujita T, Hagiwara K. 1993. Human serum mannose binding protein (MBP): development of an enzyme-linked immunosorbent assay (ELISA) and determination of levels in serum from 1085 normal Japanese and in some body fluids. Biochem. Med. Metab. Biol. 50:111-119.
38. Thern A, Stenberg L, Dahlback B, Lindahl G. 1995. Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system. J. Immunol. 154:375-386.
39. Thurman JM, Holers VM. 2006. The central role of the alternative complement pathway in human disease. J. Immunol. 176:1305-1310.
40. Walport MJ. 2001. Complement. First of two parts. N. Engl. J. Med. 344:1058-1066.
41. Wang C-Y, et al. 2012. Prc contributes to Escherichia colievasion of classical complement-mediated serum killing. Infect. Immun. 80:3399-3409.
42. Wilson CG, Kajander T, Regan L. 2005. The crystal structure of NlpI. A prokaryotic tetratricopeptide repeat protein with a globular fold. FEBS J. 272:166-179.
43. Xie Y, Yao Y, Kolisnychenko V, Teng CH, Kim KS. 2006. HbiF regulates type 1 fimbriation independently of FimB and FimE. Infect. Immun. 74: 4039-4047.
44. Yao Y, Xie Y, Kim KS. 2006. Genomic comparison of Escherichia coli K1 strains isolated from the cerebrospinal fluid of patients with meningitis. Infect. Immun. 74:2196-2206.